IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225